APP下载

氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者血浆蛋白浓度和IL-1、IL-6、IL-13水平的影响

2016-11-09倪志刚

上海医药 2016年19期
关键词:白介素

倪志刚

摘 要 目的:研究氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者尿蛋白浓度和IL-1、IL-6、IL-13水平的影响。方法:回顾性分析我院收治的59例慢性肾炎患者,按照给药方法分为对照组29例和观察组30例,对照组给予50 mg/d的氯沙坦钾,1次/d,观察组在此基础上再给予益肾化湿颗粒,3次/d,10 g/次。两组患者的疗程均为12周。观察治疗前后患者的血浆蛋白浓度、尿蛋白浓度和IL-1、IL-6、IL-13的水平变化,并分别记录其不良反应发生率。结果:经过治疗,观察组的尿蛋白浓度比对照组低(P<0.01),而血浆蛋白浓度则比对照组高(P<0.05),差异均具有统计学意义。对照组IL-6、 IL-13水平比观察组低,差异均具有统计学意义(P<0.05)。两组的IL-1水平均有下降,但差异不具有统计学意义(P>0.05)。结论:氯沙坦钾联合益肾化湿颗粒治疗慢性肾炎的疗效更好,能有效增加血浆蛋白含量,减少尿蛋白,降低血清IL-1、IL-6、IL-13的水平,不良反应较少。

关键词 氯沙坦钾 慢性肾炎 血浆蛋白 白介素

中图分类号:R286; R692.3 文献标识码:B 文章编号:1006-1533(2016)19-0034-04

Effect of losartan potassium combined with Yishenhuashi on the levels of plasma protein, IL-1, IL-6 and IL-13 in the patients with chronic glomerulonephritis*

NI Zhigang**

(Department of Nephrology, The Peoples Hospital of Yingtan City, Yingtan 335000, China)

ABSTRACT Objective: To evaluate the effect of losartan potassium combined with yishenhuashi on the levels of urine protein, IL-1, IL-6 and IL-13 in the patients with chronic glomerulonephritis. Methods: Fifty-nine cases of patients with chronic glomerulonephritis were retrospectively analyzed and divided into a control group (29 cases, treated with losartan potassium 50 mg/d qd) and an observation group (30 cases, treated with losartan potassium combined with yishenhuashi 10 g bid) and the treatment was lasted for 12 weeks. The changes of the concentrations of plasma and urine proteins and the levels of IL-1, IL-6 and IL-13 were observed before and after treatment, meanwhile the incidence of adverse reactions was recorded. Results: After treatment, the levels of urine protein were lower and the levels of plasma protein, IL-6 and IL-13 were higher in the observation group than in the control group (P<0.01). The IL-1 levels in both groups were reduced but did not show significant differences between two group. Conclusion: Losartan potassium combined with yishenhuashi has better efficacy with lower adverse reactions in the treatment of chronic glomerulonephritis, can effectively increase the plasma protein contents and reduce IL-1、IL-6 and IL-13 levels and urine protein contents.

KEY WORDS losartan potassium; chronic glomerulonephritis; plasma protein; interleukin

慢性肾炎又称慢性肾小球炎,主要临床特征为水肿、血尿、高血压、炎症等,临床上起病隐匿,病程呈渐进式炎性发展,如不及时诊治,病情将持续发展,导致不同程度的肾功能衰退甚至尿毒症[1]。目前,临床上的主要治疗方法之一是应用血管紧张素II受体拮抗剂抑制血管紧张素系统,从而达到减少尿蛋白,降低肾小管内压,缓解肾小管硬化,减少炎症发生的目的。氯沙坦钾是血管紧张素II受体拮抗剂,能有效降低肾小球内压,不良反应发生率较低[2]。本研究分析氯沙坦钾联合益肾化湿颗粒对慢性肾炎患者血浆蛋白浓度和IL-1、IL-6、IL-13水平的影响,现报道如下。

1 资料与方法

1.1 一般资料

回顾性分析2013年1月—2015年6月我院收治的59例肾炎患者。……

登录APP查看全文

猜你喜欢

白介素
氟尿嘧啶联合白介素II局封治疗多发性跖疣疗效观察
内皮素-1对牙周膜细胞肿瘤坏死因子及白介素-1β表达的影响
白介素17对鼻咽部恶性黑色素瘤血管生成的影响
白介素6上调糖尿病肾小管上皮细胞脂肪分化相关蛋白
牙龈癌患者血清白介素—6和白介素—8的水平改变与其临床病理特征分析
银屑病患儿血清肿瘤坏死因子α、白介素6、白介素8的检测
高血压病患者血清白介素6对缺血性中风诊断和辨证的临床意义探讨
哮喘患儿血清白介素与免疫球蛋白检测的临床意义
白介素25 、33 在慢性荨麻疹患者外周血中的表达及意义
寻常性银屑病患者外周血白介素17 、白介素23 mRNA 的表达及与病情相关性研究